OBJECTIVE: Combined hyperlipidemia is a common disorder, characterized by a highly atherogenic lipoprotein profile and a substantially increased risk of coronary heart disease. The purpose of this study was to establish whether variations of apolipoprotein A5 (APOA5), a newly discovered gene of lipid metabolism located 30 kbp downstream of the APOA1/C3/A4 gene cluster, contributes to the transmission of familial combined hyperlipidemia (FCHL). METHODS AND RESULTS: We performed linkage and association tests on 128 families. Two independent alleles, APOA5c.56G and APOC3c.386G, of the APOA1/C3/A4/A5 gene cluster were overtransmitted in FCHL (P=0.004 and 0.007, respectively). This was paired with reduced transmission of the common APOA1/C3/A4/A5 haplotype (frequency 0.4461) to affected subjects (P=0.012). The APOA5c.56G genotype accounted for 7.3% to 13.8% of the variance in plasma triglyceride levels in probands (P<0.004). The APOC3c.386G genotypes accounted for 4.4% to 5.1% of the variance in triglyceride levels in FCHL spouses (P<0.007), suggesting that this allele marks a FCHL quantitative trait as well as representing a susceptibility locus for the condition. CONCLUSIONS: A combined linkage and association analysis establishes that variation at the APOA1/C3/A4/A5 gene cluster contributes to FCHL transmission in a substantial proportion of northern European families.
OBJECTIVE: Combined hyperlipidemia is a common disorder, characterized by a highly atherogenic lipoprotein profile and a substantially increased risk of coronary heart disease. The purpose of this study was to establish whether variations of apolipoprotein A5 (APOA5), a newly discovered gene of lipid metabolism located 30 kbp downstream of the APOA1/C3/A4 gene cluster, contributes to the transmission of familial combined hyperlipidemia (FCHL). METHODS AND RESULTS: We performed linkage and association tests on 128 families. Two independent alleles, APOA5c.56G and APOC3c.386G, of the APOA1/C3/A4/A5 gene cluster were overtransmitted in FCHL (P=0.004 and 0.007, respectively). This was paired with reduced transmission of the common APOA1/C3/A4/A5 haplotype (frequency 0.4461) to affected subjects (P=0.012). The APOA5c.56G genotype accounted for 7.3% to 13.8% of the variance in plasma triglyceride levels in probands (P<0.004). The APOC3c.386G genotypes accounted for 4.4% to 5.1% of the variance in triglyceride levels in FCHL spouses (P<0.007), suggesting that this allele marks a FCHL quantitative trait as well as representing a susceptibility locus for the condition. CONCLUSIONS: A combined linkage and association analysis establishes that variation at the APOA1/C3/A4/A5 gene cluster contributes to FCHL transmission in a substantial proportion of northern European families.
Authors: P Pajukanta; J D Terwilliger; M Perola; T Hiekkalinna; I Nuotio; P Ellonen; M Parkkonen; J Hartiala; K Ylitalo; J Pihlajamäki; K Porkka; M Laakso; J Viikari; C Ehnholm; M R Taskinen; L Peltonen Journal: Am J Hum Genet Date: 1999-05 Impact factor: 11.025
Authors: K V Porkka; I Nuotio; P Pajukanta; C Ehnholm; L Suurinkeroinen; M Syvänne; T Lehtimäki; A T Lahdenkari; S Lahdenperä; K Ylitalo; M Antikainen; M Perola; O T Raitakari; P Kovanen; J S Viikari; L Peltonen; M R Taskinen Journal: Atherosclerosis Date: 1997-09 Impact factor: 5.162
Authors: E M Wijsman; J D Brunzell; G P Jarvik; M A Austin; A G Motulsky; S S Deeb Journal: Arterioscler Thromb Vasc Biol Date: 1998-02 Impact factor: 8.311
Authors: C Siggaard; S Rittig; T J Corydon; P H Andreasen; T G Jensen; B S Andresen; G L Robertson; N Gregersen; L Bolund; E B Pedersen Journal: J Clin Endocrinol Metab Date: 1999-08 Impact factor: 5.958
Authors: B E Aouizerat; H Allayee; R M Cantor; R C Davis; C D Lanning; P Z Wen; G M Dallinga-Thie; T W de Bruin; J I Rotter; A J Lusis Journal: Am J Hum Genet Date: 1999-08 Impact factor: 11.025
Authors: N Vu-Dac; P Gervois; I P Torra; J C Fruchart; V Kosykh; T Kooistra; H M Princen; J Dallongeville; B Staels Journal: J Clin Invest Date: 1998-08-01 Impact factor: 14.808
Authors: E Tahvanainen; P Pajukanta; K Porkka; S Nieminen; L Ikävalko; I Nuotio; M R Taskinen; L Peltonen; C Ehnholm Journal: Arterioscler Thromb Vasc Biol Date: 1998-11 Impact factor: 8.311
Authors: Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef Journal: Nat Rev Endocrinol Date: 2012-02-14 Impact factor: 43.330
Authors: G M Dallinga-Thie; A van Tol; H Hattori; L C van Vark-van der Zee; H Jansen; E J G Sijbrands Journal: Diabetologia Date: 2006-04-28 Impact factor: 10.122
Authors: Xiang Li; Tao Zhou; Hao Ma; Yoriko Heianza; Catherine M Champagne; Donald A Williamson; George A Bray; Frank M Sacks; Lu Qi Journal: Diabetes Obes Metab Date: 2020-08-20 Impact factor: 6.577
Authors: Paula Singmann; Jens Baumert; Christian Herder; Christa Meisinger; Christina Holzapfel; Norman Klopp; H-Erich Wichmann; Martin Klingenspor; Wolfgang Rathmann; Thomas Illig; Harald Grallert Journal: Obes Facts Date: 2009-07-20 Impact factor: 3.942
Authors: Yongjun Liu; Jose M Ordovas; Guimin Gao; Michael Province; Robert J Straka; Michael Y Tsai; Chao-Qiang Lai; Kui Zhang; Ingrid Borecki; James E Hixson; David B Allison; Donna K Arnett Journal: Pharmacogenet Genomics Date: 2009-02 Impact factor: 2.089